Acute myeloid leukemia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: A. Patients with acute myeloid leukemia (other than acute promyelocytic leukemia) confirmed by bone marrow examination, who had completed induction and consolidation chemotherapy, remained in residual disease-negative complete remission (CRMRD-) as assessed before enrollment, and were ineligible or unwilling to undergo hematopoietic stem cell transplantation. B. over 14 years old, regardless of gender or race; C. Physical status: ECOG score 0-3; D. Cardiac function: left ventricular ejection fraction = 40%; E. Expected survival time > 12 weeks; F. Serum creatinine (Cr) =1.5×ULN (upper limit of normal), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5×ULN, total bilirubin =1.5×ULN; G. The patient is self-aware and able to sign informed consent; The guardian of the child patient agreed to sign the informed consent. F. Lactating women were required to discontinue breastfeeding to participate in the study
Exclusion criteria
Exclusion criteria: A. Except for patients with non-remission of the primary disease or positive residual disease; B. Pregnant women, women who do not agree to stop breastfeeding during lactation; C. active HBV or HCV infection; D. People living with HIV;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| leukemia-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall?Survival;Duration of Overall Response;The incidence of adverse effects; | — |
Countries
China
Contacts
Department of Hematology of Anhui Provincial Hospital, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China